NRx Pharmaceuticals, Inc.

NasdaqCM NRXP

NRx Pharmaceuticals, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 62.50%

NRx Pharmaceuticals, Inc. Gross Profit Margin is 62.50% for the Trailing 12 Months (TTM) ending September 30, 2024. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: NRXP

NRx Pharmaceuticals, Inc.

CEO	Dr. Jonathan C. Javitt M.D., M.P.H.
IPO Date	Dec. 4, 2017
Location	United States
Headquarters	1201 Orange Street
Employees	2
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Key trends

Past 5 years